Last reviewed · How we verify
NCT05038930: MAWERIC
Mobilising Patients With Severe Brain Injury in Intensive Care
NA trial testing Mobilisation using the Sara Combilizer in Brain Injury Traumatic Severe in 22 participants. Completed in 16 March 2023.
16 March 2023
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 22 |
| Start date | 1 October 2021 |
| Primary completion | 16 March 2023 |
| Estimated completion | 16 March 2023 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Mobilisation using the Sara Combilizer
Conditions studied
- Brain Injury Traumatic Severe — all drugs for Brain Injury Traumatic Severe →
- Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
- Intracranial Hematoma — all drugs for Intracranial Hematoma →
Sponsor
Rigshospitalet, Denmark
Who can join
18 and older, any sex, with Brain Injury Traumatic Severe or Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction Patients with severe brain injury are often restricted to bed rest during the early period of brain injury which may lead to unwanted secondary complications. There is lack of evidence of when to initiate the first mobilisation. The Sara Combilizer® is an easy and efficient tool for mobilising patients with severe injuries, including brain injury. Through a randomised cross-over trial the investigators will investigate the impact of early mobilisation on patients with severe acquired brain injury caused by traumatic brain injury, subarachnoid brain injury or intracranial haematoma. The investigators hypothesise that mobilisation using the Sara Combilizer® does not affect partial oxygenation of brain tissue.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mobilising patients with severe acquired brain injury in intensive care (MAWERIC) - Protocol for a randomised cross-over trial.
Riberholt CG, Olsen MH, Berg RMG, Møller K. · · 2022 · cited 1× · PMID 35331944 · DOI 10.1016/j.cct.2022.106738
Verify or expand the search:
- PubMed search for NCT05038930
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Injury Traumatic Severe
Currently open trials in the same condition.
- NCT06480838 — Cerebral Autoregulation, Brain Perfusion, and Neurocognitive Outcomes After Traumatic Brain Injury · recruiting
- NCT04945213 — Biperiden Trial for Epilepsy Prevention · Phase 3 · recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05038930 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 10 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05038930.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing